Artificial Intelligence
Hepatic Cirrhosis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain – Madrigal, Zydus, Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Akero
<!– Name:DistributionId Value:8826847 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:adffa649-48de-4b04-aed7-5a375eec1dcf –>
New York, USA, April 27, 2023 (GLOBE NEWSWIRE) — Hepatic Cirrhosis Market Evolving at a Rapid Pace, Predicts DelveInsight | Key Companies Active in the Domain – Madrigal, Zydus, Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Akero
According to DelveInsight’s’ estimates, the hepatic cirrhosis market in 7MM is expected to show positive growth during the forecast period (2023–2032), mainly attributed to new product launches, a robust pipeline of emerging therapies, and government support for clinical development.
DelveInsight’s Hepatic Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, hepatic cirrhosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Hepatic Cirrhosis Market Report
- As per DelveInsight analysis, the hepatic cirrhosis market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- Through DelveInsight’s analysis, it can be observed that hepatic cirrhosis cases show an increasing trend in the forecasted period in the United States.
- Leading hepatic cirrhosis companies such as Madrigal Pharmaceuticals, Inc., Zydus Therapeutics Inc., PharmaIN, Rebiotix Inc., Grifols Therapeutics LLC, Exelixis, Vir Biotechnology, Inc., Lipocine Inc, Vedanta Biosciences, Inc., NGM Biopharmaceuticals, Inc, BioVie Inc., Ocelot Bio, Inc, Genfit, CymaBay Therapeutics, Inc., Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Akero Therapeutics, Inc, HighTide Biopharma Pty Ltd, Intercept Pharmaceuticals, Kowa Research Institute, Inc., COUR Pharmaceutical Development Company, Inc., and others are developing novel hepatic cirrhosis drugs that can be available in the hepatic cirrhosis market in the coming years.
- Some of the key therapies for hepatic cirrhosis treatment include Resmetirom, Saroglitazar Magnesium, PHIN-214 Subcutaneous injection, RBX7455, Albutein 20% Injectable Solution, Cabozantinib, VIR-2218, VIR-3434, LPCN 1148, VE303, Aldafermin, BIV201 continuous infusion, OCE-205, Elafibranor, Seladelpar, Namodenoson, BMS-986263, BI 685509, EFX, HTD1801, Bezafibrate, K-877-ER, CNP-104, MGL-3196, and others.
- Several hepatic cirrhosis therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major hepatic cirrhosis market share @ Hepatic Cirrhosis Market Report
Hepatic Cirrhosis Overview
Hepatic Cirrhosis is a late-stage liver condition in which good liver tissue is replaced with scar tissue, causing permanent damage to the liver. Many liver disorders and conditions cause cell death and inflammation in healthy liver cells. This is followed by cell repair and, as a result of the repair process, tissue scarring. Scar tissue obstructs blood flow through the liver, slowing its capacity to metabolize nutrients, hormones, medicines, and natural poisons. It also lowers the liver’s production of proteins and other chemicals. Cirrhosis eventually prevents the liver from functioning normally. Cirrhosis in its advanced stages is lethal.
Cirrhosis is most commonly caused by hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH) in the industrialized world, whereas hepatitis B virus (HBV) and HCV are the most common causes in the poor world. Cirrhosis can also be caused by other conditions such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure. As the liver’s function progressively declines, liver cirrhosis frequently goes untreated and unreported. As a result, it is critical to have regular exams. Abdominal ultrasonography, elastography, body magnetic resonance imaging (MRI), magnetic resonance cholangiopancreatography (MRCP), biopsies, and other imaging tests are used for hepatic cirrhosis diagnosis.
Hepatic Cirrhosis Epidemiology Segmentation
The hepatic cirrhosis epidemiology section provides insights into the historical and current hepatic cirrhosis patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The hepatic cirrhosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Hepatic Cirrhosis Prevalent Cases
- Hepatic Cirrhosis Gender-specific Cases
- Hepatic Cirrhosis Age-specific Cases
- Hepatic Cirrhosis Etiology-specific Cases
Download the report to understand which factors are driving hepatic cirrhosis epidemiology trends @ Hepatic Cirrhosis Epidemiological Insights
Hepatic Cirrhosis Treatment Market
Cirrhosis treatment techniques may differ depending on the disease stage and underlying etiology. In general, the treatment goals for compensated cirrhosis are to slow, stop, or reverse fibrosis progression and prevent decompensation events. In contrast, treatment goals for decompensated cirrhosis are to prevent further decompensation and death (e.g., by improving liver function) and to treat complications related to portal hypertension. EPCLUSA (Gilead Sciences) has been licensed by the US Food and Drug Administration to treat adult patients with chronic hepatitis C virus (HCV), both with and without cirrhosis. EPCLUSA is licensed for use in patients with moderate to severe cirrhosis in combination with the medication ribavirin.
Hepatic cirrhosis patients are also given statins and vaptans. Tolvaptan is recommended for hepatic cirrhosis treatment when renal function is preserved. Statins used in cirrhosis include atorvastatin, fluvastatin, lovastatin, pitavastatin, and simvastatin. Because of their pleiotropic qualities, statins are beneficial in the treatment of dyslipidemia in patients with liver disease. These qualities, such as alleviating endothelial dysfunction or possessing antioxidant, antifibrotic, anti-inflammatory, antiproliferative, antiangiogenic, proapoptotic, or immunomodulatory properties, are independent of their influence on cholesterol levels.
To know more about hepatic cirrhosis treatment, visit @ Hepatic Cirrhosis Treatment Drugs
Key Hepatic Cirrhosis Therapies and Companies
- Resmetirom: Madrigal Pharmaceuticals, Inc.
- Saroglitazar Magnesium: Zydus Therapeutics Inc.
- PHIN-214 Subcutaneous injection: PharmaIN
- RBX7455: Rebiotix Inc.
- Albutein 20% Injectable Solution: Grifols Therapeutics LLC
- Cabozantinib: Exelixis
- VIR-2218: Vir Biotechnology, Inc
- VIR-3434: Vir Biotechnology, Inc.
- LPCN 1148: Lipocine Inc
- VE303: Vedanta Biosciences, Inc.
- Aldafermin: NGM Biopharmaceuticals, Inc
- BIV201 continuous infusion: BioVie Inc.
- OCE-205: Ocelot Bio, Inc
- Elafibranor: Genfit
- Seladelpar: CymaBay Therapeutics, Inc.
- Namodenoson: Can-Fite BioPharma
- BMS-986263: Bristol-Myers Squibb
- BI 685509: Boehringer Ingelheim
- EFX: Akero Therapeutics, Inc
- HTD1801: HighTide Biopharma Pty Ltd
- Bezafibrate: Intercept Pharmaceuticals
- K-877-ER: Kowa Research Institute, Inc.
- CNP-104: COUR Pharmaceutical Development Company, Inc.
- MGL-3196: Madrigal Pharmaceuticals, Inc.
Learn more about the FDA-approved drugs for hepatic cirrhosis @ Drugs for Hepatic Cirrhosis Treatment
Hepatic Cirrhosis Market Dynamics
The hepatic cirrhosis market is expected to change in the coming years due to increased disease awareness and healthcare spending around the world, which will increase the size of the hepatic cirrhosis market and allow drug manufacturers to extend their hepatic cirrhosis market penetration. The United States is predicted to account for the greatest part of the hepatic cirrhosis market in the 7MM due to favorable reimbursement scenarios, increased R&D spending in pharmaceutical companies and research institutes for new medication development, and the presence of key players in the domain. In addition, due to increased awareness about new treatment options and a mature regulatory framework, Europe is expected to be the second-largest market for liver cirrhosis therapy throughout the forecast period.
Moreover, the Japanese market for liver cirrhosis treatment is expected to expand rapidly during the forecast period (2023–2032). The region’s hepatic cirrhosis market growth can be ascribed to an increase in the prevalence of liver illnesses and an improvement in healthcare infrastructure. Furthermore, the hepatic cirrhosis pipeline is highly robust; many possible therapies are being studied for hepatic cirrhosis treatment, and it is safe to assume that the therapeutic space will substantially impact the hepatic cirrhosis market throughout the forecast period.
However, certain factors may affect the growth of the hepatic cirrhosis market. The hepatic cirrhosis market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the hepatic cirrhosis market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Hepatic Cirrhosis Companies | Madrigal Pharmaceuticals, Inc., Zydus Therapeutics Inc., PharmaIN, Rebiotix Inc., Grifols Therapeutics LLC, Exelixis, Vir Biotechnology, Inc., Lipocine Inc, Vedanta Biosciences, Inc., NGM Biopharmaceuticals, Inc, BioVie Inc., Ocelot Bio, Inc, Genfit, CymaBay Therapeutics, Inc., Can-Fite BioPharma, Bristol-Myers Squibb, Boehringer Ingelheim, Akero Therapeutics, Inc, HighTide Biopharma Pty Ltd, Intercept Pharmaceuticals, Kowa Research Institute, Inc., COUR Pharmaceutical Development Company, Inc., and others |
| Key Hepatic Cirrhosis Therapies | Resmetirom, Saroglitazar Magnesium, PHIN-214 Subcutaneous injection, RBX7455, Albutein 20% Injectable Solution, Cabozantinib, VIR-2218, VIR-3434, LPCN 1148, VE303, Aldafermin, BIV201 continuous infusion, OCE-205, Elafibranor, Seladelpar, Namodenoson, BMS-986263, BI 685509, EFX, HTD1801, Bezafibrate, K-877-ER, CNP-104, MGL-3196, and others |
Scope of the Hepatic Cirrhosis Market Report
- Therapeutic Assessment: Hepatic Cirrhosis current marketed and emerging therapies
- Hepatic Cirrhosis Market Dynamics: Attribute Analysis of Emerging Hepatic Cirrhosis Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Hepatic Cirrhosis Market Access and Reimbursement
Discover more about hepatic cirrhosis drugs in development @ Hepatic Cirrhosis Clinical Trials
Table of Contents
| 1. | Hepatic Cirrhosis Market Key Insights |
| 2. | Hepatic Cirrhosis Market Report Introduction |
| 3. | Hepatic Cirrhosis Market Overview at a Glance |
| 4. | Hepatic Cirrhosis Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Hepatic Cirrhosis Treatment and Management |
| 7. | Hepatic Cirrhosis Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Hepatic Cirrhosis Marketed Drugs |
| 10. | Hepatic Cirrhosis Emerging Drugs |
| 11. | Seven Major Hepatic Cirrhosis Market Analysis |
| 12. | Hepatic Cirrhosis Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Hepatic Cirrhosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic cirrhosis companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.
Hepatic Cirrhosis Epidemiology Forecast
Hepatic Cirrhosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted hepatic cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Nonalcoholic Steatohepatitis Market
Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, Cirius Therapeutics, among others.
Non-Alcoholic Fatty Liver Disease Market
Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.
Non-Alcoholic Fatty Liver Disease Pipeline
Non-Alcoholic Fatty Liver Disease Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced non-alcoholic fatty liver disease companies, including AstraZeneca, Novartis, Pfizer, Roche, among others.
Nonalcoholic Steatohepatitis Epidemiology
Nonalcoholic Steatohepatitis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted nonalcoholic steatohepatitis epidemiology in the 7MM.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Hepatic Cirrhosis Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Artificial Intelligence
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
SINGAPORE, April 20, 2024 /PRNewswire/ — Aurionpro Solutions Limited (BSE: 532668) (NSE: AURIONPRO) announces the acquisition of Banking and Insurance focused PaaS startup, Arya.ai. With Arya.ai, Aurionpro will enhance its portfolio of enterprise fintech offerings to expedite adoption of AI that is responsible, accurate, and auditable.
Aurionpro Solutions Ltd. will acquire a majority stake (67%) in Arya.ai. This acquisition will bring products and expertise in Artificial Intelligence, Deep Learning, Intelligent Automation, PaaS, Autonomous AI Platforms, and more, to complement and strengthen Aurionpro’s industry leading portfolio.
The transaction comprises acquisition of shares held by the existing shareholders and subscription of new equity capital in the company. This will be an all-cash deal. The aggregate investment including secondary acquisition and fund infusion is approximately 16.5 MN USD.
By integrating Arya.ai’s cutting-edge AI cloud platform, with Aurionpro’s comprehensive suite of offerings, the company will create an industry leading Enterprise AI platform focused on creating value for financial institutions globally.
Commenting on the acquisition, Ashish Rai, CEO of Aurionpro Solutions, stated, “The acquisition of Arya.ai marries Aurionpro’s portfolio of industry leading enterprise software with one of the most mature Enterprise AI platforms focused on Banks and Insurers. We are incredibly excited about working with Arya.ai and our wider ecosystem partners to build out the leading Enterprise AI platform, for the financial industry worldwide.”
“Our decade long experience in building tools/platform for deep learning helped us to build a truly verticalized AI Operating System for Banking and Insurance.” Says Vinay Kumar CEO/Founder of Arya.ai. “Together with Aurionpro, we are going to build a new generation of Enterprise AI software for Banks and Insurers that truly embeds AI, augmenting a task or Autonomous Agents that can take over entire transactions”.
Founded in 2013 by Vinay Kumar and Deekshith Marla, Arya.ai has been one of the first ‘AI’ startups to use Deep Learning and deploy in enterprises. Arya.ai’s BFSI PaaS offerings include Arya API with 80+ ML models, Libra for fine-tuning SOTA ML models, and AryaXAI for AI governance.
Photo – https://mma.prnewswire.com/media/2392705/Aurionpro_solutions.jpgLogo – https://mma.prnewswire.com/media/2392706/Aurionpro_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/aurionpro-solutions-acquires-aryaai-to-power-next-generation-enterprise-ai-platforms-for-financial-institutions-302122674.html
Artificial Intelligence
Free Your Hands, QIDI Vida Smart AR Glasses Lead the Way in New Sports Experience.
NEW YORK, April 19, 2024 /PRNewswire/ — Outdoor smart AR glasses, QIDI Vida, will officially launch on 23rd April on the Kickstarter platform. QIDI Vida integrates the many functions of smart watches, sports headphones, cycling computers, heart rate monitors, and walkie-talkies using AR+AI technology, allowing users to bid farewell to cumbersome device management and enjoy outdoor sports anytime, anywhere with just one pair of glasses.
Function:
QIDI Vida uses high-tech HUD (Head-Up Display) which is similar to the technology used for aircrafts and premium cars and introduces it to the sports industry. Users can activate the HUD function at any time using voice control, enabling them to focus on the route ahead whilst simultaneously having access to information such as navigation, speed, heart rate, power and cadence, among other metrics. Another great function of the QIDI Vida is that users can also enjoy audiovisual entertainment through the optically perceived 100-inch AR HUD screen, when having some down time.
As cyclists and hikers often travel in groups, QIDI Vida supports eSIM and team functionality, allowing real-time voice communication without releasing handlebars, and users can monitor their groups’ real-time locations. The glasses also have comprehensive sensing and monitoring capabilities including temperature, humidity, UV, air pressure, geomagnetism and acceleration. In addition to obtaining environmental and health information, it also features health warnings such as altitude sickness symptoms and high heart rate, as well as fall and collision detection functions. And, in the event of danger, it can send distress signals to teammates.
Perks:
QIDI Vida has a global voice recognition and interaction feature that allows you to control all functions within the device by voice. To better provide users with an immersive sports experience, QIDI Vida’s intelligent system will have the capability to instantly gather personalised sports data, enabling it to deliver timely voice alerts and broadcasts, including the duration of exercise, distance, the environment and the weather – all tailored to the user’s preferences.
QIDI Vida enables voice-controlled photos and video recordings, allowing users to capture moments whilst cycling or hiking without the need to stop. QIDI Vida supports connections with common cycling smart hardware such as Garmin, Wahoo, Apple, and Samsung, supports GPX route files, and is compatible with professional sports apps such as Strava, Keep, Zwift, Apple Health, and All Trails.
QIDI Vida stands out for its lightweight and comfortable design with a dual lens for a full-colour data display, unlike competing AR glasses that typically have a single lens and limited colour. This innovation significantly enhances and augments the user’s sports and reality experience.
QIDI Vida will launch on the Kickstarter platform: https://www.kickstarter.com/projects/109560964/qidi-vida-smart-ar-glasses-for-sports
HIGH RES IMAGE: https://we.tl/t-epx2syiuaRWATCH VIDEO: https://www.youtube.com/watch?v=2v_Pli2pAM8&t=164s
Photo – https://mma.prnewswire.com/media/2392090/2.jpgPhoto – https://mma.prnewswire.com/media/2392092/3.jpgPhoto – https://mma.prnewswire.com/media/2392093/4.jpgPhoto – https://mma.prnewswire.com/media/2392089/1_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/free-your-hands-qidi-vida-smart-ar-glasses-lead-the-way-in-new-sports-experience-302122189.html
Artificial Intelligence
Risk Analytics Market worth $180.9 billion by 2029 – Exclusive Report by MarketsandMarkets™
CHICAGO, April 19, 2024 /PRNewswire/ — The growing use of real-time monitoring and advanced analytics, integration with cutting-edge technologies like blockchain and IoT, and an emphasis on cybersecurity, cross-industry applications, and regulatory compliance are the key factors that will shape the risk analytics market in the future. The market’s development will also be influenced by collaborative risk management, improved user experience, and an increasing focus on ESG factors and risk culture.
The Risk Analytics Market is estimated to grow from USD 59.7 billion in 2024 to USD 180.9 billion in 2029, at a CAGR of 24.8% during the forecast period, according to a new report by MarketsandMarkets™. Several trends fuel the global spread of Risk Analytics. Increasingly Increasing Data Complexity, Rising Cybersecurity Threats and Rising Adoption of Cloud-Based Solutions A growing talent pool of data scientists and engineers is building the necessary tools and infrastructure. Governments are recognizing the potential of risk analytics for economic growth and are investing in research and development. These trends make DI more accessible and valuable, leading to its global adoption.
Browse in-depth TOC on “Risk Analytics Market”260 – Tables 60 – Figures350 – Pages
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210662258
Scope of the Report
Report Metrics
Details
Market size available for years
2019–2023
Base year considered
2023
Forecast period
2024–2029
Forecast units
USD Billion
Segments Covered
Offering,Risk Type, Risk stages, Vertical, and Region.
Geographies covered
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America
Companies covered
IBM (US), SAS Institute (US), Oracle (US), FIS(US), Moody’s Analytics (US), ProcessUnity(US), ServiceNow (US), Marsh (US), Aon (UK), MetricStream (US), Resolver (Canada), SAP (Germany), Milliman(US), LogicManager(US), Provenir(US), SAI360(US), Deloitte(UK), OneTrust(US), Diligent(US), Alteryx(US), CRISIL(India), Archer(US), ZestyAI(US), Fusion Risk Management(US), RiskVille(Ireland), SPIN Analytics(UK), Kyvos Insights(US), Imperva(US), Cirium(UK), Quantexa(UK), ClickUp(US), Sprinto(US), Ventiv(US), Adenza(US), Centrl.AI(Canada), SafetyCulture(Australia), Quantifi(US), CubeLogic(UK), Onspring(US), Riskoptics(US)
By offering the services segment to account for higher CAGR during the forecast period
In the Risk Analytics Market, the highest CAGR of services is fueled by Increasing Complexity of Risks, AI and machine learning advancements, big data analytics integration, business process optimization, cloud-based solutions adoption, data-driven culture, and diverse industry adoption. These trends reflect a global shift towards leveraging data for competitive advantage, driving a continuous need for sophisticated risk analytics services across sectors. As businesses prioritize agility, the growth of services in the Risk Analytics Market is driven by the need for effective risk management strategies in an increasingly complex and uncertain business environment.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=210662258
By Type, GRC software is expected to hold the largest market size for the year 2024
GRC software typically offers comprehensive solutions that cover a wide range of risk management needs, including compliance management, policy management, audit management, and risk assessment. They also provide organizations with enhanced visibility into their risk landscape. Through features such as risk assessment, risk monitoring, and reporting, organizations can identify and prioritize risks more effectively, enabling proactive risk management strategies. GRC software streamlines risk management processes through automation, reducing manual effort and increasing efficiency. Tasks such as risk assessments, control testing, and incident management can be automated, freeing up resources to focus on strategic risk mitigation efforts. the combination of comprehensive functionality, regulatory compliance support, efficiency gains, scalability, integration capabilities, and culture enhancement makes GRC software a preferred choice for many organizations seeking to manage risk effectively.
By Vertical, Healthcare & Life Sciences is projected to grow at the highest CAGR during the forecast period
The Healthcare and Lifesciences is experiencing a surge in the adoption of risk analytics due to a confluence of factors. Healthcare providers and life sciences companies wants to ensure the safety and well-being of patients. Risk analytics helps in identifying potential risks to patient safety, such as medication errors, adverse events, and medical device failures. The healthcare and life sciences industries are heavily regulated, with strict guidelines for patient care, data privacy, drug development, and clinical trials. Risk analytics helps organizations ensure compliance with these regulations by identifying and mitigating risks of non-compliance. Healthcare organizations and life sciences companies also face financial risks associated with fraud, billing errors, revenue cycle management, and reimbursement challenges. Risk analytics helps in detecting anomalies and optimizing financial processes to mitigate these risks.
Asia Pacific is expected to grow at the highest CAGR during the forecast period
The Asia-Pacific (APAC) region is experiencing rapid growth in the Risk Analytics Market, boasting the highest Compound Annual Growth Rate (CAGR). This surge is primarily attributed to rising demand for data-driven decision-making solutions, expanding digital transformation initiatives across industries.. Moreover, the region’s favorable regulatory environment, growing investments in big data analytics, and the integration of advanced technologies like the Internet of Things (IoT) further propel APAC’s dominance in Risk Analytics Market growth.
Top Key Companies in Risk Analytics Market:
The major risk analytics software and service providers include IBM (US), SAS Institute (US), Oracle (US), FIS(US), Moody’s Analytics (US), ProcessUnity(US), ServiceNow (US), Marsh (US), Aon (UK), MetricStream (US), Resolver (Canada), SAP (Germany), Milliman(US), LogicManager(US), Provenir(US), SAI360(US), Deloitte(UK), OneTrust(US), Diligent(US), Alteryx(US), CRISIL(India), Archer(US), ZestyAI(US), Fusion Risk Management(US), RiskVille(Ireland), SPIN Analytics(UK), Kyvos Insights(US), Imperva(US), Cirium(UK), Quantexa(UK), ClickUp(US), Sprinto(US), Ventiv(US), Adenza(US), Centrl.AI(Canada), SafetyCulture(Australia), Quantifi(US), CubeLogic(UK), Onspring(US), Riskoptics(US). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the Risk Analytics Market.
Recent Developments:
In March 2024, Orcale announced Oracle Risk Management Cloud in Release 24B. It offers comprehensive solution designed to help organizations identify, assess, and mitigate risks across their business operations. It offers advanced analytics, automation, and collaboration tools to streamline risk management.In March 2024, FIS Global announces card fraud detection capabilities leveraging artificial intelligence (AI) with aim to bolster FIS’s ability to identify and prevent fraudulent transactions, providing greater security for cardholders and financial institutions alike.In March 2024, Aon acquired an AI-powered platform to assist fleet and mobility clients in making data-driven decisions, enhancing operational efficiency and risk management. The platform utilizes artificial intelligence to analyze data and provide insights, enabling clients to optimize their fleet operations and improve decision-making processes.In March 2024, Crisp joined Resolver, with the aim to enhance Resolver’s risk intelligence capabilities by integrating Crisp’s expertise and technology into its platform, offering clients improved risk assessment and mitigation tools.In February 2024, SAS partnered with Carahsoft to bring analytics, AI, and data management solutions to the public sector. The aim is to leverage SAS’s expertise in advanced analytics and Carahsoft’s extensive government market reach to offer tailored solutions that enable public sector organizations to harness the power of data for informed decision-making and improved outcomes.Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=210662258
Risk Analytics Market Advantages:
By offering insights into potential risks, opportunities, and trends, risk analytics helps organisations make data-driven decisions that improve strategic planning and resource allocation.In order to improve risk management procedures and lessen exposure to possible threats, risk analytics solutions assist businesses in identifying, evaluating, and mitigating risks across a range of business activities, including finance, operations, and compliance.Through real-time monitoring and anomaly detection made possible by risk analytics, organisations may proactively address shifting market situations, legal requirements, and cybersecurity threats.Risk analytics solutions assist organisations lower operating costs, increase productivity, and streamline compliance activities, which results in cost savings and resource optimisation. They do this by streamlining risk management procedures and automating routine work.Accurate risk assessments, audit trails, and reporting capabilities are just a few of the ways that risk analytics solutions help organisations comply with regulations and stay out of trouble.Organisations can enhance their resilience and competitiveness by anticipating and mitigating potential hazards before they materialise through the use of predictive modelling and advanced analytics approaches in risk analytics.Report Objectives
To define, describe, and predict the Risk Analytics Market by offering, risk type, risk stages, vertical, and regionTo provide detailed information about the major factors (drivers, restraints, opportunities, and challenges) influencing the market growthTo analyze the opportunities in the market and provide details of the competitive landscape for stakeholders and market leadersTo forecast the market size of segments with respect to five main regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin AmericaTo profile the key players and comprehensively analyze their market rankings and core competenciesTo analyze the competitive developments, such as partnerships, product launches, and mergers & acquisitions, in the Risk Analytics MarketBrowse Adjacent Markets: Analytics Market Research Reports & Consulting
Related Reports:
Customer Data Platform Market – Global Forecast to 2028
Speech Analytics Market- Global Forecast to 2029
Text to Video AI Market – Global Forecast to 2027
Contact Center Analytics Market- Global Forecast to 2027
Procurement Analytics Market- Global Forecast to 2026
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:Mr. Aashish MehraMarketsandMarkets™ INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [email protected] Insight: https://www.marketsandmarkets.com/ResearchInsight/risk-analytics-market.aspVisit Our Website: https://www.marketsandmarkets.com/Content Source: https://www.marketsandmarkets.com/PressReleases/risk-analytics.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/risk-analytics-market-worth-180-9-billion-by-2029—exclusive-report-by-marketsandmarkets-302121085.html
-
Artificial Intelligence6 days agoSilent Eight secures AIA as its latest client
-
Artificial Intelligence3 days agoHuawei Introduces AI Technologies to Accelerate Network Transformation Towards All Intelligence in the Net5.5G Era
-
Artificial Intelligence6 days agoGlobal Networking Innovator Huawei Leads the New Era of Campus Network Technology
-
Artificial Intelligence5 days agoBroadcom Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Delivering Reliable and Flexible Hybrid Cloud Management Solutions
-
Artificial Intelligence5 days agoGFT teams up with Google Cloud to launch ‘GenAI Intelligent Assistant’
-
Artificial Intelligence4 days agovLex Launches Vastly Expanded Vincent Legal GenAI Toolset, and AI-Focused Co-Development Lab
-
Artificial Intelligence5 days agoELEGOO Adds Two New Innovations To Its Saturn Series, Ushering In A New Era Of Precision 3D Printing
-
Artificial Intelligence4 days agoGEP NAMED ‘LEADER’ IN MULTIPLE GLOBAL PROCUREMENT SERVICES REPORTS BY TOP ANALYST FOR FOURTH YEAR IN A ROW
